FRNM
Freenome, Inc.
Set alert
12.48 USD -0.38 -2.95%
11.59 Day range 12.71
9.99 52-week range 17.11
- YTD
- -4.22%
- 1 year
- +16.64%
- Open
- 12.64
- Prev close
- 12.86
- Mkt cap
- 1.34B
- Vol
- 651.14K
- Avg vol
- 842.36K
- EPS
- -2.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.59
- High
- 12.71
- Forward P/E
- -5.19
- Beta
- 0.45
- Short ratio
- 4.91
- Inst. own
- 42.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 14.76
- 200-d avg
- 12.52
- 1y target
- 18.00
Key statistics
- Market cap
- 1.34B
- Enterprise value
- 2.95B
- Trailing P/E
- 0.00
- Forward P/E
- -5.19
- PEG ratio
- 0.00
- Price / sales
- 37.78
- Price / book
- 0.00
- EPS (TTM)
- -2.04
- Beta
- 0.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 35.41M
- Revenue growth
- 106.50%
- Free cash flow
- 0
- Total cash
- 102.02M
- Total debt
- 311.45M
- Return on equity
- 0.00%
- Shares outstanding
- 107.45M
- Short % of float
- 0.00%
- 50-day average
- 14.76
- 200-day average
- 12.52
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 18.00 +44.2% upside
Now 12.48
- Target (low)
- 17.00
- Target (mean)
- 18.00
- Target (high)
- 21.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate -0.195.
Financials — quick view
FRNM Revenue — quarterly 4.22M
FRNM Net income — quarterly -63.56M
FRNM EPS — quarterly -2.38
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | 0.1375 | — | — | — |
| Jul 15, 2026 | Jun 30, 2026 | -1.78 | -1.91 | -0.13 | -7.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2026 | Guggenheim | init | — | Buy |
| Aug 18, 2026 | TD Cowen | init | — | Buy |
| Aug 17, 2026 | Jefferies | init | — | Buy |
| Aug 17, 2026 | BTIG | init | — | Buy |
About Freenome, Inc.
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- freenome.com
News
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests
- Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
- Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
- Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
- Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
- Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
- Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
- Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
- Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock
Your note
Sign in to keep a note on FRNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMAN MICHAEL SETH | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 0 |
| EDELMAN JOSEPH E | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 19, 2026 | 0 |
| MCKENNA MARK C | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 30,000 |
| PERCEPTIVE CAPITAL SOLUTIONS HOLDINGS | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 19, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 19, 2026 | 0 |
| SONG KENNETH M.D. | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 30,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citizens Financial Group Inc/RI | 0.64% | 684,946 | 8.53M | Sep 29, 2026 |
| Wealth Enhancement Advisory Services, LLC | 0.27% | 290,453 | 3.62M | Sep 29, 2026 |
| FNY Investment Advisers, LLC | 0.00% | 3,500 | 43.57K | Sep 29, 2026 |
| SBI Securities Co., Ltd. | 0.00% | 1,155 | 14.38K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Venture Fund | 1.88% | 2,019,291 | 25.14M | Jul 30, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 0.69% | 742,035 | 9.24M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.37% | 397,340 | 4.95M | Aug 30, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Global Stock Fd. | 0.22% | 238,855 | 2.97M | Jul 30, 2026 |
| Federated Hermes World Investment Series, Inc.-Federated Hermes Intl S | 0.09% | 100,000 | 1.24M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Total U.S. Stock Market ETF | 0.08% | 82,521 | 1.03M | Sep 29, 2026 |